Tag Directory / HEALTHCARE     showing 1–9 of 9

for: Saturday, February 28, 2026



After 4-Week Strike, Kaiser Permanente Workers Score Tentative Win on Staffing & Pay / MedCity

Katie Adams / medcitynews - About 31,000 Kaiser Permanente workers ended a four-week strike after reaching a tentative agreement that includes measures to address chronic understaffing and wage increases. The full contract has not yet been ratified.The post After 4-Week Strike, Kais…

#healthcare #publichealth #hospitaloperations #healthcarefinance

The Kaiser Settlement Should End the Guesswork in Medicare Advantage Oversight

6 days / medcitynews / David Lareau

2,400 Kaiser mental health workers to hold 1-day strike

6 days / beckershospitalreview / Kelly Gooch

Your Anesthesia Subsidy: Key Questions Every Hospital C-Suite Must Answer

9 days / beckershospitalreview / Vedant Bhosale

Four Proven Approaches to Stabilizing Clinical Operations

9 days / beckershospitalreview / Vedant Bhosale

Clinician Engagement: The Operating Lever Behind Margin and Throughput

9 days / beckershospitalreview / Vedant Bhosale

Work environment, moral resilience help nurses prevent moral injury

9 days / medicalxpress

After 4-Week Strike, Kaiser Permanente Workers Score Tentative Win on Staffing & Pay

13 days / medcitynews / Katie Adams

31,000 Kaiser workers end strike; mental health clinicians back walkout: 6 notes

15 days / beckershospitalreview / Kelly Gooch

Saturday, February 28, 2026, 12:22 pm / permalink 19945 / 8 stories in 10 days


Merck Splits Oncology Business Unit as Keytruda Patent Expiry Nears / OncoDaily

oncodaily - On February 23, 2026, Merck announced a reorganization of its Human Health structure into two business units: an Oncology Business Unit and a Specialty, Pharma & Infectious Diseases Business Unit. […]

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #healthcarefinance

Merck KGaA drops two cancer trials on assets from SpringWorks deal

6 days / endpoints / Reynald Castaneda

No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC

8 days / esmo

Cancer Research UK partners with the Royal College of Surgeons of England to help people with rectal cancer avoid unnecessary surgery

8 days / cancerresearchuk / Krishna Sharma

A domain-adaptive deep contrastive network for magnetic resonance imaging-driven bladder cancer classification

8 days / nature

Multicenter ex vivo evaluation of an α-mannosidase–targeted fluorescent probe for intraoperative margin assessment in breast cancer

8 days / nature

Neoadjuvant pembrolizumab plus chemotherapy in older patients with early-stage triple-negative breast cancer: real-world insights from neo-real/GBECAM-0123

8 days / nature

Merck looks to expand Welireg label following combo readouts with Keytruda, Lenvima

11 days / endpoints / Nicole DeFeudis

Merck Splits Oncology Business Unit as Keytruda Patent Expiry Nears

12 days / oncodaily

Merck reorganizes; Blackstone to fund trials for J&J drug

16 days / endpoints / ENDPOINTS

Saturday, February 28, 2026, 3:22 am / permalink 19937 / 9 stories in 11 days


Teladoc Health reports slower growth, offers cautious 2026 outlook as it shifts telehealth model / Fierce

fiercehealthcare - Teladoc Health reported better-than-expected fourth quarter financial results with both revenue and earnings exceeding analysts' expectations, driving a 15% jump in the company's stock Thursday.

#healthcare #governmentpolicy #digitalhealth #healthcarefinance

Why Telehealth Skills Belong at the Core of Clinical Education

10 days / beckershospitalreview / Nikhil Gaikwad

Teladoc Health reports slower growth, offers cautious 2026 outlook as it shifts telehealth model

12 days / fiercehealthcare

Teladoc projects lower integrated care membership amid ACA subsidy lapse

12 days / healthcaredive / Emily Olsen

Saturday, February 28, 2026, 3:22 am / permalink 19936 / 3 stories in 11 days


CFO Mark Kaye to take the helm at Carelon in leadership shake-up at Elevance Health / Fierce

fiercehealthcare - Elevance Health Chief Financial Officer Mark Kaye will grow his list of duties to include oversight of Carelon, the company announced Thursday.

#healthcare #digitalhealth #behavioralhealth #healthcarefinance

CMS threatens Elevance with Medicare Advantage sanctions

8 days / healthcaredive / Rebecca Pifer Parduhn

CMS set to suspend enrollment in Elevance Health's Medicare Advantage plans

8 days / fiercehealthcare

CMS to suspend enrollment into Elevance’s Medicare Advantage plans

9 days / beckershospitalreview / Elizabeth Casolo

How Leading Health Systems Are Mastering the Next Capacity Surge

9 days / beckershospitalreview / Vedant Bhosale

Elevance shuffles C-suite as top Carelon exec departs

12 days / healthcaredive / Rebecca Pifer Parduhn

CFO Mark Kaye to take the helm at Carelon in leadership shake-up at Elevance Health

12 days / fiercehealthcare

Saturday, February 28, 2026, 2:21 am / permalink 19934 / 6 stories in 11 days


First-ever in-utero stem cell therapy for fetal spina bifida repair shows safe results / Medical Express

medicalxpress - A Phase I clinical trial published in The Lancet has shown that combining stem cell therapy with standard fetal surgery before birth is a safe and promising approach to treat myelomeningocele, a severe form of spina bifida. This is the first time live ste…

#healthcare #biotech #drugdevelopment #infanthealth

Stem cell patch reverses brain damage in fetuses with spina bifida

12 days / newscientist

First-ever in-utero stem cell therapy for fetal spina bifida repair shows safe results

12 days / medicalxpress

Saturday, February 28, 2026, 1:22 am / permalink 19931 / 2 stories in 11 days


Microplastics discovered in prostate tumors / Medical Express

medicalxpress - Small fragments of plastic were found in 9 out of 10 patients with prostate cancer, and in higher levels inside tumors than in nearby noncancerous tissue, a new study finds. The small, single-center study was led by researchers at NYU Langone Health, its …

#healthcare #publichealth #oncology

How worried should you be about microplastics?

7 days / newscientist

María Natalia Gandur Quiroga: Structural Shifts in How We Think About Prostate Cancer

10 days / oncodaily

Microplastics found in 90% of prostate cancer tumors, study reveals

14 days / sciencedaily

Microplastics discovered in prostate tumors

15 days / medicalxpress

Saturday, February 28, 2026, 12:23 am / permalink 19928 / 4 stories in 11 days


Boehringer wins accelerated approval for first-line use of lung cancer drug / Endpoints

Lei Lei Wu / endpoints - The FDA greenlit an expanded label for Boehringer Ingelheim’s lung cancer drug Hernexeos, marking the first use of the Commissioner's National Priority Voucher for a new indication. Boehringer won an accelerated

#healthcare #pharmaceuticals #publichealth #governmentpolicy #biotech #drugdevelopment #fda #oncology

What to know about lung cancer

6 days / medicalxpress

Lurbinectedin in Oncology: Mechanism, Clinical Data, Evolving Role, and Future Directions

9 days / oncodaily

Patrick Soon-Shiong: Anktiva Plus Keytruda Shows Potential to Prolong Survival in Patients with Lung Cancer

10 days / oncodaily

Aakash Desai HER2-Mutant NSCLC: Navigating the TKI vs ADC Debate

10 days / oncodaily

Stephen V Liu: Intracranial Efficacy of Trastuzumab Deruxtecan in HER2-Mutant NSCLC

10 days / oncodaily

FDA Approves Zongertinib for HER2-Mutated NSCLC – Oncology Brothers

10 days / oncodaily

Zongertinib Receives FDA Accelerated Approval in HER2-Mutant NSCLC

11 days / oncodaily

FDA Voucher Leads to Speedy Approval of Boehringer Drug for First-Line Use in Lung Cancer

12 days / medcitynews / Frank Vinluan

Boehringer wins accelerated approval for first-line use of lung cancer drug

12 days / endpoints / Lei Lei Wu

Saturday, February 28, 2026, 12:23 am / permalink 19927 / 9 stories in 11 days


Novartis to build $23B radioligand therapy site / Beckers

Ella Jeffries / beckershospitalreview - Novartis will construct a 46,000-square-foot radioligand therapy manufacturing site in Denton, Texas, as part of its $23 billion U.S. investment. The facility will be Novartis’ fifth radioligand therapy site in the U.S. and its first in Texas, according t…

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #healthcarefinance

Oklahoma pharmacy school to expand radiopharmaceutical access with new facility

6 days / beckershospitalreview / Ella Jeffries

Novartis to build $23B radioligand therapy site

12 days / beckershospitalreview / Ella Jeffries

Novartis to build another radioligand factory; Germany steps up probe into Gerresheimer

13 days / endpoints / Anna Brown

Saturday, February 28, 2026, 12:23 am / permalink 19926 / 3 stories in 11 days


Patient dies in MacroGenics' cancer study, FDA puts trial on hold / Endpoints

Max Gelman / endpoints - The FDA has placed a partial clinical hold on MacroGenics’ Phase 2 study in gynecologic cancers after one patient died and three others experienced life-threatening side effects, the company disclosed Tuesday. The patient who died ...

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda #oncology

Kyowa Kirin ends OX40 trials after Amgen balked, safety concern

7 days / endpoints / Kyle LaHucik

FDA partially pauses cancer drug trial after patient death

13 days / beckershospitalreview / Paige Twenter

Patient dies in MacroGenics' cancer study, FDA puts trial on hold

15 days / endpoints / Max Gelman

Saturday, February 28, 2026, 12:23 am / permalink 19925 / 3 stories in 11 days


Back to Top


HEALTHCARE Heatmap

90 days, weeks are vertical, left is older; hover for info, click to see that day's coverage.



More Top Stories...

FDA refuses to review Moderna mRNA flu vaccine application

Moderna’s mRNA flu vaccine application has been rejected by the FDA—Moderna received a refusal‐to‐file letter while accusing the agency of shifting its review standards. Multiple reports echo this regulatory setback, fueling industry concerns over consistent, transparent decision‐making. More...


FDA CRL halts AstraZeneca’s Saphnelo prefilled pen approval

AstraZeneca’s application to market its subcutaneous prefilled pen formulation of Saphnelo for treating lupus has hit a roadblock after the FDA issued a complete response letter. The decision delays the drug’s approval and raises questions about its future in the competitive immunotherapy market. More...


CMS proposes sweeping changes to ACA marketplace plan rules

CMS has proposed a major rule reshaping Affordable Care Act marketplace policies, including loosening limits on non-standard plan designs and promoting lower-premium options such as catastrophic coverage. The agency says the changes will reduce costs and boost flexibility, while critics warn they could increase confusion and weaken consumer protections—because shopping for insurance clearly wasn’t complicated enough. More...


Tenet forecasts major ACA exchange enrollment drop and financial hit

Tenet Healthcare is warning that the expiration of enhanced Affordable Care Act premium tax credits will drive a steep reduction in ACA exchange enrollment, projecting a significant revenue impact in 2026. Despite the headwind, the company says it expects earnings growth, leaning on acuity and operational performance—because nothing calms Wall Street like “we’ll make it up somewhere else.” More...


City of Hope promotes Nisha Morris to senior marketing chief

City of Hope named Nisha Morris as Senior Vice President and Chief Marketing and Communications Officer, adding marketing leadership to its executive team. The move signals a renewed focus on brand, outreach, and patient engagement as the cancer center sharpens its communication and growth strategies. More...


NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.